Siddhant Kabra, a part of the promoter group of Eiko Lifesciences Limited, has acquired 47,000 equity shares of the company through open market transactions on March 17, 2025. The acquisition represents 0.33% of the company’s total issued and subscribed equity shares, bringing Kabra’s total holding to 5,63,650 shares, equivalent to a 4.06% stake in Eiko Lifesciences.
This development was disclosed under Regulation 29(1) of SEBI’s Substantial Acquisition of Shares and Takeovers (SAST) Regulations, 2011. Prior to the acquisition, Kabra held 5,16,650 shares, representing a 3.72% stake in the company. The total equity share capital of Eiko Lifesciences remains unchanged at ₹13.86 crore, comprising 1,38,60,445 equity shares of ₹10 each.
The transaction reflects continued confidence from the promoter group in the company’s growth prospects. Investors and market participants will closely watch if further stake increases follow in the coming quarters.
Disclaimer: Investments in stock markets are subject to risks. Investors are advised to conduct their due diligence before making investment decisions.
